Loading current stock analysis…
Loading current stock analysis…
India
Reported ownership for FY2026-Q4 as of 2026-03-31.
As of 25 Sept 2026, 03:30 pm
J.B. Chemicals & Pharmaceuticals Limited was amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective from January 21, 2026. The National Company Law Tribunal (NCLT) sanctioned the Scheme of Amalgamation on July 6, 2026, with the certified order received on July 7, 2026. The company was officially dissolved on July 8, 2026, after filing the certified copies of the order and scheme with the Registrar of Companies, Ahmedabad.
J.B. Chemicals & Pharmaceuticals Limited shareholders are entitled to receive Torrent Pharmaceuticals Limited shares. The record date to determine eligible shareholders was set as July 17, 2026. According to the approved amalgamation scheme, shareholders will receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held. Torrent Pharma shares have a face value of ₹5 each, while J. B. Chemicals shares had a face value of ₹1 each.
As of September 23, 2026, the closing price for J.B. Chemicals & Pharmaceuticals Limited was ₹2,408.9. The market capitalization on this date was ₹386,769,866,883.4.
As of 25 Sept 2026, 03:30 pm
There is not enough history to make a reliable risk assessment.
Latest complete financial results for Q4 FY2026 and comparative quarterly trends.
| Metric | Q4 FY2025-26(Latest) | Q3 FY2025-26 | Q2 FY2025-26 | Q1 FY2025-26 | Q4 FY2024-25 |
|---|---|---|---|---|---|
| Revenue From Operations | ₹904.23 crore | ₹1,064.72 crore | ₹1,084.90 crore | PEAK₹1,093.94 crore | ₹949.48 crore |
| Profit Before Exceptional Items And Tax | ₹161.87 crore | ₹266.87 crore | PEAK₹279.15 crore | ₹271.61 crore | ₹193.03 crore |
| Exceptional Items Before Tax | -₹27.18 crore | PEAK₹0.0 | PEAK₹0.0 | PEAK₹0.0 | PEAK₹0.0 |
| Profit Before Tax | ₹134.69 crore | ₹266.87 crore | PEAK₹279.15 crore | ₹271.61 crore | ₹193.03 crore |
| Finance Costs | ₹1.23 crore | PEAK₹1.88 crore | ₹1.35 crore | ₹1.11 crore | ₹1.45 crore |
| Other Expenses | ₹230.12 crore | ₹248.05 crore | ₹241.55 crore | PEAK₹251.68 crore | ₹224.58 crore |
Pre-tax profit (PBT) closed at ₹134.69 crore, reflecting a 30.2% year-on-year decline and a 49.5% sequential fall. The reported results include an exceptional item before tax of –₹27.18 crore for the quarter, which was not present in the four preceding quarters. This charge accounted for roughly one-fifth of the sequential drop in pre-tax profit, with the remainder stemming from the lower underlying operating profitability.
Paid-up equity share capital increased to ₹16.06 crore at the end of the quarter, up from ₹15.57 crore a year earlier. The face value of shares remained unchanged at ₹1 per share.
The quarter concluded with a notable pullback in sales and earnings. Profitability contracted more steeply than revenue because operating expenses, particularly employee costs and general overheads, decreased at a slower rate. An additional exceptional charge further weighed on pre-tax results. The performance marks a clear deceleration from the higher revenue and profit levels recorded in the first three quarters of the fiscal year.
Exchange disclosures and regulatory announcements for J.B. Chemicals & Pharmaceuticals.
On July 8, 2026, J. B. Chemicals & Pharmaceuticals Limited (JB Chemicals) was amalgamated with and dissolved into Torrent Pharmaceuticals Limited, effective from the Appointed Date of January 21, 2026. This follows the approval and sanction of the Scheme of Amalgamation by the National Company Law Tribunal (NCLT) on July 6, 2026, with the certified order received on July 7, 2026. The certified copies of the order and scheme were filed with the Registrar of Companies, Ahmedabad, on July 8, 2026.
J. B. Chemicals & Pharmaceuticals Limited has fixed July 17, 2026, as the record date to determine shareholders entitled to receive Torrent Pharmaceuticals Limited shares as per the approved amalgamation scheme. Shareholders will receive 51 Torrent Pharma shares for every 100 J. B. Chemicals shares held, with Torrent Pharma shares having a face value of Rs. 5 each and J. B. Chemicals shares having a face value of Re. 1 each. This follows the National Company Law Tribunal's order dated July 6, 2026, sanctioning the amalgamation.
The National Company Law Tribunal, Ahmedabad Bench, sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited on July 6, 2026. J. B. Chemicals & Pharmaceuticals Limited received the certified true copy of this order on July 7, 2026.
J.B. Chemicals & Pharmaceuticals Limited received a certificate from its Registrar and Share Transfer Agents, Datamatics Business Solutions Limited, confirming compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. This certificate covers the quarter ended June 30, 2026, and verifies that securities received for dematerialization were mutilated, cancelled, and replaced with the depository as the registered owner within 15 days of receipt.
The Hon'ble National Company Law Tribunal, Ahmedabad Bench, has sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The sanction was granted via an order dated July 6, 2026. The Scheme will become effective upon filing the certified copy of the order with the Registrar of Companies.
J.B. Chemicals & Pharmaceuticals Limited announced the retirement of two senior management personnel, Mr. Pradeep Kumar Singh (President Global Business) and Mr. Suresh Bhise (Vice President – IT), effective June 30, 2026. This disclosure is made in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
J.B. Chemicals & Pharmaceuticals Limited will close its trading window from July 1, 2026, until 48 hours after the declaration of its unaudited financial results for the quarter ending June 30, 2026. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations.
J.B. Chemicals & Pharmaceuticals Limited held its 50th Annual General Meeting on June 17, 2026, through video conference. All resolutions, including the adoption of financial statements for the year ended March 31, 2026, confirmation of an interim dividend of Rs. 12.70 per share, declaration of a final dividend of Rs. 9.30 per share, and the re-appointment of Mr. Amal Kelshikar as a director, were approved by the shareholders with a significant majority. The voting results were based on consolidated reports from the appointed scrutinizer.
Comprehensive Section Breakdown for J.B. Chemicals & Pharmaceuticals
Strategic Vision: Manufactures and markets diverse pharmaceutical products globally.
Category: Manufacturing
Engaged in the manufacturing and marketing of a diverse range of pharmaceutical products, including generic and branded generics across various therapeutic categories.
• Extensive global distribution network across over 40 countries.
• Multiple world-class manufacturing facilities with numerous international accreditations.
• Broad therapeutic area coverage and diverse product dosage forms.
J.B. Chemicals & Pharmaceuticals reported a contraction in both sales and earnings for the quarter ended March 2026. Revenue fell 4.8% compared to the same period last year and dropped 15.1% from the preceding quarter. Profit before tax declined more sharply, falling 30.2% year-on-year and 49.5% sequentially, driven by a slower reduction in operating costs and a reported exceptional charge.
Revenue from operations totaled ₹904.23 crore in the fourth quarter, down from ₹949.48 crore a year earlier and ₹1,064.72 crore in the third quarter. Over the fiscal year, sales peaked at ₹1,093.94 crore in the first quarter and trended downward through the second and third quarters before the steeper decline in the final quarter.
Profit before exceptional items and tax (PBEIT) followed a similar path, settling at ₹161.87 crore. This represents a 16.1% decrease from the prior-year quarter and a 39.3% drop from the previous quarter. As a percentage of revenue, PBEIT margin compressed from 20.3% a year ago and 25.1% in the third quarter to 17.9% in the current quarter. The wider drop in profit compared to revenue indicates that operating costs did not scale down proportionally with the sales decline.
Total operating expenses came to ₹754.34 crore, a 2.2% decrease year-on-year and a 7.6% decrease from the third quarter. While expenses declined, the pace of reduction lagged behind the double-digit sequential drop in revenue.
Key expense components for the quarter include:
Employee benefits and other expenses combined made up 56.8% of total costs. Both categories showed limited responsiveness to the revenue contraction; other expenses actually rose 2.5% year-on-year to ₹230.12 crore despite lower sales.
Core Thesis: The company leverages its manufacturing capabilities and global presence to deliver a diverse portfolio of pharmaceutical products across multiple therapeutic areas.
• Global Operations: Maintains a global presence with operations and exports to over 40 countries, including a strong foothold in Russia, Ukraine, and CIS nations. • Manufacturing Excellence: Operates 8 world-class manufacturing facilities, with 7 in Gujarat, India, holding over 40 global accreditations and utilizing sophisticated technologies. • Diverse Product Portfolio: Offers a comprehensive product portfolio spanning gastroenterology, hypertension, dermatology, and expanding into newer areas like nephrology, respiratory, and diabetes.